TORONTO, ONTARIO--(Marketwired - Nov 24, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M ...

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma ...

TORONTO, ONTARIO--(Marketwired - Nov. 24, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M ® ...

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc.

TORONTO, ONTARIO--(Marketwired - Nov 24, 2014) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M ® ...

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc ...

MISSISSAUGA, Ontario, April 15, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”,“the Company”, TSX Venture: RX) is pleased to announce that its wh ...

(2024-04-15 | TSXV:RX) BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies.